Third generation in bio-electrochemical system research – A systematic review on mechanisms for recovery of valuable by-products from wastewater

2017 ◽  
Vol 76 ◽  
pp. 1022-1031 ◽  
Author(s):  
Dipak A. Jadhav ◽  
Sreemoyee Ghosh Ray ◽  
Makarand M. Ghangrekar
Keyword(s):  
Systematic Review ◽  
Third Generation ◽  
System Research ◽  
Electrochemical System ◽  
By Products

Clinical Use of Third-Generation 3D Imaging Systems in Endoscopic Surgery—a Systematic Review

2021 ◽  
Author(s):  
Jaime Vilaça ◽  
José Moreira de Azevedo ◽  
Hugo Cardoso Louro ◽  
Jorge Correia Pinto ◽  
Pedro Leão
Keyword(s):  
Systematic Review ◽  
Endoscopic Surgery ◽  
3D Imaging ◽  
Imaging Systems ◽  
Third Generation ◽  
Clinical Use

Comparison of resistance to third-generation cephalosporins inShigellabetween Europe-America and Asia-Africa from 1998 to 2012

2015 ◽  
Vol 143 (13) ◽  
pp. 2687-2699 ◽  
Author(s):  
B. GU ◽  
M. ZHOU ◽  
X. KE ◽  
S. PAN ◽  
Y. CAO ◽  
...  
Keyword(s):  
Systematic Review ◽  
Drug Resistance ◽  
Confidence Interval ◽  
Literature Search ◽  
Third Generation ◽  
Rational Use ◽  
Total Prevalence ◽  
Rational Use Of Antibiotics ◽  
Resistance Rates ◽  
Third Generation Cephalosporins

SUMMARYWe conducted a systematic review to compare resistance to third-generation cephalosporins (TGCs) inShigellastrains between Europe-America and Asia-Africa from 1998 to 2012 based on a literature search of computerized databases. In Asia-Africa, the prevalence of resistance of total and different subtypes to ceftriaxone, cefotaxime and ceftazidime increased markedly, with a total prevalence of resistance up to 14·2% [95% confidence interval (CI) 3·9–29·4], 22·6% (95% CI 4·8–48·6) and 6·2% (95% CI 3·8–9·1) during 2010–2012, respectively. By contrast, resistance rates to these TGCs in Europe-America remained relatively low – less than 1·0% during the 15 years. A noticeable finding was that certain countries both in Europe-America and Asia-Africa, had a rapid rising trend in the prevalence of resistance ofS. sonnei, which even outnumberedS. flexneriin some periods. Moreover, comparison between countries showed that currently the most serious problem concerning resistance to these TGCs appeared in Vietnam, especially for ceftriaxone, China, especially for cefotaxime and Iran, especially for ceftazidime. These data suggest that monitoring of the drug resistance ofShigellastrains should be strengthened and that rational use of antibiotics is required.

scholarly journals Heterogeneity in the Relationship between Disinfection By-Products in Drinking Water and Cancer: A Systematic Review

2018 ◽  
Vol 15 (5) ◽  
pp. 979 ◽  
Author(s):  
Tarik Benmarhnia ◽  
Ianis Delpla ◽  
Lara Schwarz ◽  
Manuel Rodriguez ◽  
Patrick Levallois
Keyword(s):  
Systematic Review ◽  
Drinking Water ◽  
The Relationship ◽  
By Products

scholarly journals Comparing the Performance of HIV Rapid Diagnostic Tests Used in Zambia: a Systematic Review of Clinical Data.

2021 ◽  
Author(s):  
Loveness Mukuka ◽  
Andros Theo ◽  
Mowa Zambwe ◽  
Peter J Chipimo
Keyword(s):  
Systematic Review ◽  
Clinical Data ◽  
Diagnostic Tests ◽  
Rapid Diagnostic Tests ◽  
Fourth Generation ◽  
Hiv Positive ◽  
Third Generation ◽  
Predictive Values ◽  
Rapid Tests ◽  
Positive Results

Objective: To investigate the performance of the HIV RDTs used in Zambia. Method: 2,564 participants aged between 15 and 95 years from two sites in Lusaka province years were tested on OraQuick ADVANCE, Abbot Determine, and then confirmed on Uni-Gold Recombigen. The data from the participants were analyzed using SPSS version 25.0. Results: The 3 RDTs when compared to the 4th generation Abbot Architect results had the following results: OraQuick ADVANCE, Alere Determine and Uni-Gold Ultra, at 95% CI had Sensitivities of: 91.8%, 93.3% and 92.5% respectively. The specificities of OraQuick ADVANCE and Uni-Gold were the same (100.0%; 95% CI: 98.8 -100.0) but slightly different from Alere Determine (99.8%). Positive predictive values at 95% CI were 100% for OraQuick ADVANCE and Uni-Gold and 98.4% for Alere Determine. Negative predictive values (at 95% CIs) were 99.1, 99.2 and 99.1 for OraQuick ADVANCE, Alere Determine, and Uni-Gold Ultra respectively. The results showed that these RDTs could only detect 12 out of every 13 HIV positive results. Conclusion: Third generation RDTs are not effective in detecting acute positive cases. Fourth generation Rapid Tests are required to capture the positive cases being missed out.

scholarly journals Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Olga Mulas ◽  
Giovanni Caocci ◽  
Brunella Mola ◽  
Giorgio La Nasa
Keyword(s):  
Systematic Review ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Cardiovascular Complication ◽  
Third Generation ◽  
Pubmed Database

Background: Off-target effects in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) are associated with cardiovascular toxicity. Hypertension represents an important cardiovascular complication and, if not appropriately managed, can contribute to developing thrombotic events. Third-generation TKI ponatinib is associated with hypertension development, and its use is more restricted than in the past. Few data are reported for second-generation TKI, nilotinib, dasatinib, and bosutinib. The aim of this article was to evaluate with a systematic review and meta-analysis the real incidence of hypertension in CML patients treated with second- or third-generation TKI.Methods: The PubMed database, Web of Science, Scopus, and ClinicalTrials.gov were systematically searched for studies published between January 1, 2000, and January 30, 2021; the following terms were entered in the database queries: Cardiovascular, Chronic Myeloid Leukemia, CML, Tyrosine kinases inhibitor, TKI, and Hypertension. The study was carried out according to the Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA) statement.Results: A pooled analysis of hypertension incidence was 10% for all new-generation TKI, with an even higher prevalence with ponatinib (17%). The comparison with the first-generation imatinib confirmed that nilotinib was associated with a significantly increased risk of hypertension (RR 2; 95% CI; 1.39-2.88, I2=0%, z=3.73, p=0.0002). The greatest risk was found with ponatinib (RR 9.21; 95% CI; 2.86-29.66, z=3.72, p=0.0002).Conclusion: Hypertension is a common cardiovascular complication in CML patients treated with second- or third-generation TKI.

scholarly journals A 27-year Meta-analysis of Ankle Arthroplasty

2018 ◽  
Vol 3 (3) ◽  
pp. 2473011418S0023 ◽  
Author(s):  
Christopher Gross ◽  
Steven Haddad ◽  
Jesse Morris ◽  
Elizabeth Durante ◽  
Philip Kirn
Keyword(s):  
Systematic Review ◽  
Second Generation ◽  
Revision Rate ◽  
Meta Analysis ◽  
Total Ankle Arthroplasty ◽  
Complication Rates ◽  
Third Generation ◽  
Early Generation ◽  
Previous Systematic Review ◽  
Ankle Arthroplasty

Category: Ankle Arthritis Introduction/Purpose: Total ankle arthroplasty is an alternative to ankle arthrodesis for the treatment of end-stage arthritis while maintaining greater ankle motion and functionality. Early generation implants had unacceptably high complication rates. However, increasing surgical experience and newer third-generation designs have the potential to offer better outcomes. A previous systematic review reported results from studies published between 1990 and 2005, focusing on second-generation implants. We performed a systematic review of the literature addressing the intermediate-long-term outcomes of interest in total ankle arthroplasty studies published since 2006, and we compared our findings to those from earlier generation implants. Methods: A comprehensive search of MEDLINE for all articles published from 3/25/2006 to 2/1/2017 was conducted with a minimum two-year follow-up. Two reviewers evaluated each study to determine whether it was eligible for inclusion and abstracted the data of interest. Meta-analytic pooling of group results across studies was performed. The analysis focused on third-generation ankle implants. Results: The previous systematic review identified 10 studies (n=852), whereas we identified 40 studies (n=4835). The prior study showed a five and ten-year survival rate of 78% and 77%, respectively; respective rates were 86% (p=0.001) and 76% (p=0.53) in ours and similar to the previous study. The revision rate following TAR was 7% in the earlier review (loosening/subsidence, 28%). In ours, the revision rate following TAR was 9.6% (p=0.10) (component loosening, 37%); 3.4% (p=0.02) of ankles were converted to arthrodesis. The mean post-operative Ankle-Hindfoot score was 78.2 points in the prior review and 80.1 (p=0.20) points for ours. There is significant (p<0.0001) heterogeneity (I2=92.94%) between the studies; a meta-analysis of proportions showed that 81.6%of subjects had good outcomes while 46.6% had an excellent outcome. Conclusion: Based on these findings, the outcomes for third-generation total ankle arthroplasty have no significant differences in survival rates when compared to second-generation implants. However, functional scores, range of motion, and overall patient outcomes were significantly higher in the third-generation implants. However, data from early generation studies were sparse in comparison, so direct comparative studies are needed to strengthen this conclusion.

Sign in / Sign up

Export Citation Format

Share Document